Top

Published in:

Open Access 13-11-2023 | Alzheimer's Disease | Review Article

Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease

Authors: Jeffrey Cummings, Amanda M. Leisgang Osse, Davis Cammann, Jayde Powell, Jingchun Chen

Published in: BioDrugs | Issue 1/2024

Abstract

Two monoclonal antibodies (mAbs), aducanumab and lecanemab, have received accelerated approval from the US FDA for initiation of treatment in early Alzheimer's disease patients who have proven β-amyloid pathology (Aβ). One of these, lecanemab, has subsequently received full approval and other monoclonal antibodies are poised for positive review and approval. Anti-amyloid mAbs share the feature of producing a marked reduction in total brain Aβ revealed by amyloid positron emission tomography. Trials associated with slowing of cognitive decline have achieved a reduction in measurable plaque Aβ in the range of 15–25 centiloids; trials of agents that did not reach this threshold were not associated with cognitive benefit. mAbs have differences in terms of titration schedules, MRI monitoring schedules for amyloid-related imaging abnormalities (ARIA), and continuing versus interrupted therapy. The approximate 30% slowing of decline observed with mAbs is clinically meaningful in terms of extended cognitive integrity and delay of onset of the more severe dementia phases of Alzheimer’s disease. Approval of these agents initiates a new era in Alzheimer’s disease therapeutics with disease-modifying properties. Further advances are needed, i.e. greater efficacy, improved safety, enhanced convenience, and better understanding of ill-understood observations such as brain volume loss.

Feigin VL, Nichols E, Alam T, Bannick MS, Beghi E, Blake N, et al. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(5):459–80.CrossRef

Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, et al. Two randomized phase 3 studies of aducanumab in early Alzheimer’s disease. J Prev Alzheimers Dis. 2022;9(2):197–210.PubMed

Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimer’s Res Ther. 2021;13(1):80.CrossRef

van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer’s disease. N Engl J Med. 2023;388(1):9–21.PubMedCrossRef

Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, et al. Donanemab in early Alzheimer’s disease. N Engl J Med. 2021;384(18):1691–704.PubMedCrossRef

Sperling RA, Jack CR, Black SE, Frosch MP, Greenberg SM, Hyman BT, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer’s Association Research Roundtable Workgroup. Alzheimer’s Dementia. 2011;7(4):367–85.CrossRef

Cummings J, Rabinovici GD, Atri A, Aisen P, Apostolova LG, Hendrix S, et al. Aducanumab: appropriate use recommendations update. J Prev Alzheimers Dis. 2022;9(2):221–30.PubMedPubMedCentral

Cummings J, Apostolova L, Rabinovici GD, Atri A, Aisen P, Greenberg S, et al. Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis. 2023;10(3):362–77. https://doi.org/10.14283/jpad.2023.30.CrossRefPubMedPubMedCentral

Arndt JW, Qian F, Smith BA, Quan C, Kilambi KP, Bush MW, et al. Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β. Sci Rep. 2018;8(1):6412.PubMedPubMedCentralCrossRef

10.

Söderberg L, Johannesson M, Nygren P, Laudon H, Eriksson F, Osswald G, et al. Lecanemab, aducanumab, and gantenerumab—binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for Alzheimer’s disease. Neurotherapeutics. 2023;20(1):195–206.PubMedCrossRef

11.

Haddad HW, Malone GW, Comardelle NJ, Degueure AE, Kaye AM, Kaye AD. Aducanumab, a novel anti-amyloid monoclonal antibody, for the treatment of Alzheimer’s disease: a comprehensive review. Health Psychol Res. 2022;10(1):31925.PubMedPubMedCentralCrossRef

12.

Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400(6740):173.PubMedCrossRef

13.

Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer’s disease. Nature. 2000;408(6815):982–5.PubMedCrossRef

14.

Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005;64(9):1553–62.PubMedCrossRef

15.

Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology. 2003;61(1):46–54.PubMedCrossRef

16.

Nicoll JAR, Barton E, Boche D, Neal JW, Ferrer I, Thompson P, et al. Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol. 2006;65(11):1040–8.PubMedCrossRef

17.

Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, et al. Long-term effects of Abeta42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008;372(9634):216–23.PubMedCrossRef

18.

Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology. 2009;73(24):2061–70.PubMedPubMedCentralCrossRef

19.

Vandenberghe R, Rinne JO, Boada M, Katayama S, Scheltens P, Vellas B, et al. Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials. Alzheimers Res Ther. 2016;8(1):18.PubMedPubMedCentralCrossRef

20.

Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370(4):322–33.PubMedPubMedCentralCrossRef

21.

Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer’s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010;9(4):363–72.PubMedCrossRef

22.

Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370(4):311–21.PubMedCrossRef

23.

Zhang Y, Lee DHS. Sink hypothesis and therapeutic strategies for attenuating Abeta levels. Neuroscientist. 2011;17(2):163–73.PubMedCrossRef

24.

Honig LS, Vellas B, Woodward M, Boada M, Bullock R, Borrie M, et al. Trial of solanezumab for mild dementia due to Alzheimer’s disease. N Engl J Med. 2018;378(4):321–30.PubMedCrossRef

25.

Cummings JL, Cohen S, van Dyck CH, Brody M, Curtis C, Cho W, et al. ABBY: a phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease. Neurology. 2018;90(21):e1889–97.PubMedPubMedCentralCrossRef

26.

Salloway S, Honigberg LA, Cho W, Ward M, Friesenhahn M, Brunstein F, et al. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer’s disease (BLAZE). Alzheimers Res Ther. 2018;10(1):96.PubMedPubMedCentralCrossRef

27.

Ostrowitzki S, Bittner T, Sink KM, Mackey H, Rabe C, Honig LS, et al. Evaluating the safety and efficacy of crenezumab vs placebo in adults with early Alzheimer disease: two phase 3 randomized placebo-controlled trials. JAMA Neurol. 2022;79(11):1113–21.PubMedPubMedCentralCrossRef

28.

Ostrowitzki S, Lasser RA, Dorflinger E, Scheltens P, Barkhof F, Nikolcheva T, et al. A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease. Alzheimers Res Ther. 2017;9(1):95.PubMedPubMedCentralCrossRef

29.

FDA Office of the Commissioner. FDA. FDA; 2023 [cited 31 May 2023]. FDA Grants Accelerated Approval for Alzheimer’s Disease Treatment. https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-disease-treatment

30.

Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature. 2016;537(7618):50–6.PubMedCrossRef

31.

Bussiere T, Weinreb PH, Dunstan RW, Qian F, Arastu MF, Li M, et al. Differential in vitro and in vivo binding profiles of BIIB037 and other anti-abeta clinical antibody candidates. Neurodegener Dis. 2013. https://misc.karger.com/websites/NDD_2013_011_s_1/AbstractCD/pdf/787.pdf.

32.

Biogen. A randomized, blinded, placebo-controlled single ascending dose study of the safety, tolerability, and pharmacokinetics of biib037 in subjects with mild to moderate Alzheimer’s disease. ClinicalTrials.gov; 2015 Mar [cited 23 Mar 2023]. Report No. NCT01397539. Available at: https://clinicaltrials.gov/ct2/show/NCT01397539.

33.

Ferrero J, Williams L, Stella H, Leitermann K, Mikulskis A, O’Gorman J, et al. First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer’s disease. Alzheimer’s Dementia. 2016;2(3):169–76.PubMedCentral

34.

Biogen. A randomized, double-blinded, placebo-controlled multiple dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of BIIB037 in subjects with prodromal or mild Alzheimer’s disease. ClinicalTrials.gov; 2020 Jul [cited 23 Mar 2023]. Report No. NCT01677572. https://clinicaltrials.gov/ct2/show/NCT01677572.

35.

Biogen. A phase 2, multicenter, randomized, parallel-group, double-blind, controlled study of aducanumab (BIIB037) in subjects with mild cognitive impairment due to Alzheimer’s disease or with mild Alzheimer’s disease dementia to evaluate the safety of continued dosing in subjects with asymptomatic amyloid-related imaging abnormalities. ClinicalTrials.gov; 2021 Aug [cited 30 Mar 2023]. Report No. NCT03639987. https://clinicaltrials.gov/ct2/show/NCT03639987.

36.

Salloway S, Chalkias S, Barkhof F, Burkett P, Barakos J, Purcell D, et al. Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease. JAMA Neurol. 2022;79(1):13–21.PubMedCrossRef

37.

Biogen. A phase 3 multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aducanumab (BIIB037) in subjects with early Alzheimer’s disease. ClinicalTrials.gov; 2021 Aug [cited 30 Mar 2023]. Report No. NCT02477800. https://clinicaltrials.gov/ct2/show/NCT02477800.

38.

Biogen. A phase 3 multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aducanumab (BIIB037) in subjects with early Alzheimer’s disease. ClinicalTrials.gov; 2021 Aug [cited 22 Mar 2023]. Report No. NCT02484547. https://clinicaltrials.gov/ct2/show/NCT02484547.

39.

Herring WL, Gould IG, Fillit H, Lindgren P, Forrestal F, Thompson R, et al. Predicted lifetime health outcomes for aducanumab in patients with early Alzheimer’s disease. Neurol Ther. 2021;10(2):919–40.PubMedPubMedCentralCrossRef

40.

von Rosenstiel P, Haeberlein SB, Castrillo-Viguera C, Chen T, O’Gorman J, Rajagovindan R, et al. Aducanumab 48-month analyses from PRIME, a phase 1b study in patients with early Alzheimer’s disease. 11th Clinical Trials on Alzheimer’s Disease Congress 2018; 2018 [cited 23 Aug 2023]; Barcelona, Spain. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571451/.

41.

Englund H, Sehlin D, Johansson AS, Nilsson LNG, Gellerfors P, Paulie S, et al. Sensitive ELISA detection of amyloid-β protofibrils in biological samples. J Neurochem. 2007;103(1):334–45.PubMedCrossRef

42.

FDA Office of the Commissioner. Eisai Newsroom. 2023. FDA Approves LEQEMBI™ (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer’s Disease [cited 31 May 2023]. https://media-us.eisai.com/2023-01-06-FDA-Approves-LEQEMBI-TM-lecanemab-irmb-Under-the-Accelerated-Approval-Pathway-for-the-Treatment-of-Alzheimers-Disease.

43.

Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, Forsell C, et al. The “Arctic” APP mutation (E693G) causes Alzheimer’s disease by enhanced Aβ protofibril formation. Nat Neurosci. 2001;4(9):887–93.PubMedCrossRef

44.

Lord A, Gumucio A, Englund H, Sehlin D, Sundquist VS, Söderberg L, et al. An amyloid-β protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer’s disease. Neurobiol Dis. 2009;36(3):425–34.PubMedCrossRef

45.

Sehlin D, Englund H, Simu B, Karlsson M, Ingelsson M, Nikolajeff F, et al. Large aggregates are the major soluble Aβ species in AD brain fractionated with density gradient ultracentrifugation. PLoS ONE. 2012;7(2): e32014.PubMedPubMedCentralCrossRef

46.

Logovinsky V, Satlin A, Lai R, Swanson C, Kaplow J, Osswald G, et al. Safety and tolerability of BAN2401—a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody. Alzheimer’s Res Ther. 2016;8(1):14.CrossRef

47.

Satlin A, Wang J, Logovinsky V, Berry S, Swanson C, Dhadda S, et al. Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer’s disease. Alzheimer’s Dementia. 2016;2(1):1–12.PubMedCentral

48.

Rauchenberger R, Borges E, Thomassen-Wolf E, Rom E, Adar R, Yaniv Y, et al. Human combinatorial Fab library yielding specific and functional antibodies against the human fibroblast growth factor receptor 3. J Biol Chem. 2003;278(40):38194–205.PubMedCrossRef

49.

Novakovic D, Feligioni M, Scaccianoce S, Caruso A, Piccinin S, Schepisi C, et al. Profile of gantenerumab and its potential in the treatment of Alzheimer’s disease. Drug Des Dev Ther. 2013;7:1359–64.

50.

Bohrmann B, Baumann K, Benz J, Gerber F, Huber W, Knoflach F, et al. Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β. J Alzheimers Dis. 2012;28(1):49–69.PubMedCrossRef

51.

Hoffmann-La Roche. A single-dose study to investigate the safety, tolerability, and pharmacokinetics (PK) of gantenerumab following subcutaneous (SC) administration in healthy volunteers. ClinicalTrials.gov; 2019 Apr [cited 30 May 2023]. Report No. NCT02711423. https://clinicaltrials.gov/ct2/show/NCT02711423.

52.

Hoffmann-La Roche. A multiple ascending dose study of R1450 in patients with Alzheimer disease. ClinicalTrials.gov; 2016 Nov [cited 30 May 2023]. Report No. NCT00531804. https://clinicaltrials.gov/ct2/show/NCT00531804.

53.

Ostrowitzki S, Deptula D, Thurfjell L, Barkhof F, Bohrmann B, Brooks DJ, et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol. 2012;69(2):198–207.PubMedCrossRef

54.

Hoffmann-La Roche. A study of gantenerumab in participants with prodromal Alzheimer’s disease (Scarlet Road). ClinicalTrials.gov; 2021 Dec [cited 30 May 2023]. Report No. NCT01224106. https://clinicaltrials.gov/ct2/show/NCT01224106.

55.

Washington University School of Medicine. Dominantly inherited Alzheimer network trial: an opportunity to prevent dementia. a study of potential disease modifying treatments in individuals at risk for or with a type of early onset Alzheimer’s disease caused by a genetic mutation. Master Protocol DIAN-TU-001 (DIAN-TU). ClinicalTrials.gov; 2023 May [cited 30 May 2023]. Report No. NCT01760005. https://clinicaltrials.gov/ct2/show/NCT01760005.

56.

Joseph-Mathurin N, Llibre-Guerra JJ, Li Y, McCullough AA, Hofmann C, Wojtowicz J, et al. Amyloid-related imaging abnormalities in the DIAN-TU-001 trial of gantenerumab and solanezumab: lessons from a trial in dominantly inherited Alzheimer disease. Ann Neurol. 2022;92(5):729–44.PubMedPubMedCentralCrossRef

57.

Hoffmann-La Roche. Efficacy and safety study of gantenerumab in participants with early Alzheimer’s disease (AD). ClinicalTrials.gov; 2023 Apr [cited 30 May 2023]. Report No. NCT03444870. https://clinicaltrials.gov/ct2/show/NCT03444870.

58.

Boess F, Sakaoka S, Abi-Saab D, Scelsi MA, Delmar P, Hofmann C, et al. Graduation study design: evaluation of once-weekly subcutaneous administration of gantenerumab on brain amyloid load. Alzheimer’s Dementia. 2021;17(S9): e052060.CrossRef

59.

DeMattos RB, Lu J, Tang Y, Racke MM, DeLong CA, Tzaferis JA, et al. A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer’s disease mice. Neuron. 2012;76(5):908–20.PubMedCrossRef

60.

Bouter Y, Liekefeld H, Pichlo S, Westhoff AC, Fenn L, Bakrania P, et al. Donanemab detects a minor fraction of amyloid-β plaques in post-mortem brain tissue of patients with Alzheimer’s disease and Down syndrome. Acta Neuropathol. 2022;143(5):601–3.PubMedPubMedCentralCrossRef

61.

Lowe SL, Willis BA, Hawdon A, Natanegara F, Chua L, Foster J, et al. Donanemab (LY3002813) dose-escalation study in Alzheimer’s disease. Alzheimers Dement (N Y). 2021;7(1): e12112.PubMedCrossRef

62.

Lowe SL, Duggan Evans C, Shcherbinin S, Cheng YJ, Willis BA, Gueorguieva I, et al. Donanemab (LY3002813) phase 1b study in Alzheimer’s disease: rapid and sustained reduction of brain amyloid measured by florbetapir F18 imaging. J Prev Alzheimers Dis. 2021;8(4):414–24.PubMed

63.

Shcherbinin S, Evans CD, Lu M, Andersen SW, Pontecorvo MJ, Willis BA, et al. Association of amyloid reduction after donanemab treatment with tau pathology and clinical outcomes: the TRAILBLAZER-ALZ randomized clinical trial. JAMA Neurol. 2022;79(10):1015–24.PubMedPubMedCentralCrossRef

64.

Pontecorvo MJ, Lu M, Burnham SC, Schade AE, Dage JL, Shcherbinin S, et al. Association of donanemab treatment with exploratory plasma biomarkers in early symptomatic alzheimer disease: a secondary analysis of the TRAILBLAZER-ALZ randomized clinical trial. JAMA Neurol. 2022;79(12):1250–9.PubMedPubMedCentralCrossRef

65.

Eli Lilly and Company. Lilly—News Release. 2023. Lilly’s Donanemab Significantly Slowed Cognitive and Functional Decline in Phase 3 Study of Early Alzheimer’s Disease. https://investor.lilly.com/news-releases/news-release-details/lillys-donanemab-significantly-slowed-cognitive-and-functional.

66.

Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512–27.PubMedCrossRef

67.

Eli Lilly and Company. Lilly—News Release. 2023. U.S. Food and Drug Administration Issues Complete Response Letter for Accelerated Approval of Donanemab. https://investor.lilly.com/news-releases/news-release-details/us-food-and-drug-administration-issues-complete-response-0.

68.

Alzforum. 2023. Remternetug [cited 26 Apr 2023]. https://www.alzforum.org/therapeutics/remternetug.

69.

Alzforum. 2023. International conference on Alzheimer’s and Parkinson’s diseases 2023: next goals for immunotherapy: make it safer, less of a hassle. https://www.alzforum.org/news/conference-coverage/next-goals-immunotherapy-make-it-safer-less-hassle.

70.

Pardridge WM. Blood-brain barrier drug delivery of IgG fusion proteins with a transferrin receptor monoclonal antibody. Expert Opin Drug Deliv. 2015;12(2):207–22.PubMedCrossRef

71.

Cummings J, Zhou Y, Lee G, Zhong K, Fonseca J, Cheng F. Alzheimer’s disease drug development pipeline: 2023. Alzheimers Dement (N Y). 2023;9(2): e12385.PubMedCrossRef

72.

Cummings J. Anti-amyloid monoclonal antibodies are transformative treatments that redefine Alzheimer’s disease therapeutics. Drugs. 2023;83(7):569–76.PubMedPubMedCentralCrossRef

73.

Cummings J, Aisen P, Apostolova LG, Atri A, Salloway S, Weiner M. Aducanumab: appropriate use recommendations. J Prev Alzheimers Dis. 2021;8(4):398–410.PubMedPubMedCentral

74.

Perneczky R, Jessen F, Grimmer T, Levin J, Flöel A, Peters O, et al. Anti-amyloid antibody therapies in Alzheimer’s disease. Brain. 2023;146(3):842–9.PubMedCrossRef

75.

Salvadó G, Molinuevo JL, Brugulat-Serrat A, Falcon C, Grau-Rivera O, Suárez-Calvet M, et al. Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers. Alzheimer’s Res Ther. 2019;11(1):27.CrossRef

76.

Jagust WJ, Landau SM. Temporal dynamics of β-amyloid accumulation in aging and Alzheimer disease. Neurology. 2021;96(9):e1347–57.PubMedPubMedCentralCrossRef

77.

Farrell ME, Jiang S, Schultz AP, Properzi MJ, Price JC, Becker JA, et al. Defining the lowest threshold for amyloid-PET to predict future cognitive decline and amyloid accumulation. Neurology. 2021;96(4):e619–31.PubMedPubMedCentralCrossRef

78.

Milà-Alomà M, Ashton NJ, Shekari M, Salvadó G, Ortiz-Romero P, Montoliu-Gaya L, et al. Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease. Nat Med. 2022;28(9):1797–801.PubMedPubMedCentral

79.

Doré V, Krishnadas N, Bourgeat P, Huang K, Li S, Burnham S, et al. Relationship between amyloid and tau levels and its impact on tau spreading. Eur J Nucl Med Mol Imaging. 2021;48(7):2225–32.PubMedPubMedCentralCrossRef

80.

Ossenkoppele R, Pichet Binette A, Groot C, Smith R, Strandberg O, Palmqvist S, et al. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nat Med. 2022;28(11):2381–7.PubMedPubMedCentralCrossRef

81.

Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol. 2013;12(4):357–67.PubMedCrossRef

82.

Dunn B, Stein P, Temple R, Cavazzoni P. An appropriate use of accelerated approval—aducanumab for Alzheimer’s disease. N Engl J Med. 2021;385(9):856–7.PubMedCrossRef

83.

Cummings J, Aisen P, Lemere C, Atri A, Sabbagh M, Salloway S. Aducanumab produced a clinically meaningful benefit in association with amyloid lowering. Alzheimer’s Res Ther. 2021;13(1):98.CrossRef

84.

Dickson SP, Wessels AM, Dowsett SA, Mallinckrodt C, Sparks JD, Chatterjee S, et al. ‘Time saved’ as a demonstration of clinical meaningfulness and illustrated using the donanemab TRAILBLAZER-ALZ study findings. J Prev Alzheimers Dis. 2023;10(3):595–9. https://doi.org/10.14283/jpad.2023.50.CrossRefPubMed

85.

Petersen RC, Aisen PS, Andrews JS, Atri A, Matthews BR, Rentz DM, et al. Expectations and clinical meaningfulness of randomized controlled trials. Alzheimer’s & Dementia. 2023;19(6):2730–6.CrossRef

86.

Tahami Monfared AA, Ye W, Sardesai A, Folse H, Chavan A, Aruffo E, et al. A path to improved Alzheimer’s care: simulating long-term health outcomes of lecanemab in early Alzheimer’s disease from the CLARITY AD trial. Neurol Ther. 2023;12(3):863–81.PubMedPubMedCentralCrossRef

87.

Assunção SS, Sperling RA, Ritchie C, Kerwin DR, Aisen PS, Lansdall C, et al. Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease. Alzheimer’s Res Ther. 2022;14(1):54.CrossRef

88.

Sveikata L, Charidimou A, Viswanathan A. Vessels sing their ARIAs: the role of vascular amyloid in the age of aducanumab. Stroke. 2022;53(1):298–302.PubMedCrossRef

89.

Alves F, Kalinowski P, Ayton S. Accelerated brain volume loss caused by anti-β-amyloid drugs: a systematic review and meta-analysis. Neurology. 2023;100(20):e2114–24.PubMedCrossRef

90.

Sur C, Kost J, Scott D, Adamczuk K, Fox NC, Cummings JL, et al. BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer’s disease brain. Brain. 2020;143(12):3816–26.PubMedPubMedCentralCrossRef

Title: Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease
Authors: Jeffrey Cummings
Amanda M. Leisgang Osse
Davis Cammann
Jayde Powell
Jingchun Chen
Publication date: 13-11-2023
Publisher: Springer International Publishing
Keywords: Alzheimer's Disease
Alzheimer's Disease
Positron Emission Tomography
Published in: BioDrugs / Issue 1/2024
Print ISSN: 1173-8804
Electronic ISSN: 1179-190X
DOI: https://doi.org/10.1007/s40259-023-00633-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2024

Is the Availability of Biosimilar Adalimumab Associated with Budget Savings? A Difference-in-Difference Analysis of 14 Countries

Immunotherapy Guided by Immunohistochemistry PD-L1 Testing for Patients with NSCLC: A Microsimulation Model-Based Effectiveness and Cost-Effectiveness Analysis

Advancing Subcutaneous Dosing Regimens for Biotherapeutics: Clinical Strategies for Expedited Market Access

Ixekizumab for Active Radiographic Axial Spondyloarthritis in Chinese Patients: 16- and 52-Week Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study

Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What Have We Learned?

Dystrophin- and Utrophin-Based Therapeutic Approaches for Treatment of Duchenne Muscular Dystrophy: A Comparative Review